Results 31 to 40 of about 194,414 (305)
Anticoagulation in pulmonary arterial hypertension: a decision analysis
Pulmonary Circulation, 2019 Systemic anticoagulation may be beneficial in pulmonary arterial hypertension, but there is no randomized clinical trial data to guide therapeutic decision making, and current guidelines do not account for patient preferences or quality of life. Decision
Arun Jose +2 more
doaj +1 more source
Pulmonary Circulation, 2021 Inhalation profiles to support use of dry powder inhalers for drug delivery in patients with pulmonary arterial hypertension have not been reported. We aimed to evaluate the inspiratory flow pattern associated with low and medium flow resistance dry ...
Mariana Faria-Urbina +4 more
doaj +1 more source
Right ventriculo–pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension
Pulmonary Circulation, 2020 Right ventricular function critically affects the prognosis of patients with pulmonary arterial hypertension. We aimed to analyze the prognostic value of right ventricular indices calculated using magnetic resonance imaging and right heart ...
Toshitaka Nakaya +8 more
doaj +1 more source
Pulmonary Circulation, 2022 Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability.
Mauricio Orozco‐Levi +11 more
doaj +1 more source
Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood
, 2005 BACKGROUND: Pulmonary arterial hypertension (PAH) is a potentially fatal vasculopathy that can develop at any age. Adult-onset disease has previously been associated with mutations in BMPR2 and ALK-1.
Haworth, SG +22 more
core +1 more source
Effect of Pomegranate Extract (Punica Granatum L) on Pulmonary Arterial Pressure in Sprague Dawley Rat with Pulmonary Arterial Hypertension [PDF]
, 2020 Congenital heart disease causes pulmonary arterial hypertension, heart failure, and early death. Pulmonary arterial hypertension causes pulmonary arterial wall remodeling, inflammation, deposition of extracellular matrix protein, collagen synthesis, and ...
Taufiq Hidayat, - +2 more
core
Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. [PDF]
, 2015 In patients with idiopathic pulmonary arterial hypertension (iPAH), iron deficiency is common and has been associated with reduced exercise capacity and worse survival. Previous studies have shown beneficial effects of intravenous iron administration. In
Ruiter, G +35 more
core +1 more source
Diagnostic tools in pulmonary arterial hypertension management
, 2010 An accurate differential diagnosis is crucial in pulmonary hypertension/pulmonary arterial hypertension (PH/PAH), because the treatment options in the different PH/PAH groups and subgroups differ substantially.
Vonk Noordegraaf, Anton +6 more
core +1 more source
Biomarkers in Pulmonary Arterial Hypertension
Diagnostics, 2022 Pulmonary arterial hypertension (PAH) is a severe medical condition characterized by elevated pulmonary vascular resistance (PVR), right ventricular (RV) failure, and death in the absence of appropriate treatment. The progression and prognosis are strictly related to the etiology, biochemical parameters, and treatment response.
Silvana Elena Hojda +2 more
openaire +3 more sources
Schistosomiasis Pulmonary Arterial Hypertension [PDF]
Frontiers in Immunology, 2020 Pulmonary arterial hypertension (PAH) is a disease of the lung blood vessels that results in right heart failure. PAH is thought to occur in about 5% to 10% of patients with hepatosplenic schistosomiasis, particularly due to S. mansoni. The lung blood vessel injury may result from a combination of embolization of eggs through portocaval shunts into the
Jean Pierre Sibomana +24 more
openaire +5 more sources